Jul. 08 – New Jersey-based Ikaria Holdings Inc. will pay $285 million to lsraeli company BioLineRx to obtain a worldwide exclusive license to develop and market BioLineRx?s BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction (AMI), the Israeli company has announced. BL-1040, currently in a phase I/II clinical trial, is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle, where it forms a protective “scaffold” that enhances the mechanical strength of the heart muscle during recovery and repair. It was invented by Professor Smadar Cohen from Ben-Gurion University and Professor Jonathan Leor from Tel-Aviv University. Under the terms of the agreement, BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange, will receive upfront and milestone payments and reserves the right to produce BL-1040 in Israel. It would supply Ikaria with part of its demand. Ikaria will be responsible for completing clinical development and commercialization efforts. The deal is contingent upon receipt of the approval of Israeli Office of the Chief Scientist. BioLineRx is dedicated to developing promising therapeutics for unmet medical needs. The company’s leading programs are BL-1040 and BL-1020 for the treatment of schizophrenia.
#News
US company buys exclusive license for Israeli heart attack drug for $285 million
By ISRAEL21c Staff
July 8, 2009, 12:00 am
Read more on: News
-
By Brian Blum
-
By Brian Blum
Latest Articles
Apr 22, 2:19 pm
Wake up and smell the peace
Apr 22, 8:15 am
Tel Aviv University launches VC fund for students, alumni
Apr 22, 8:11 am
New algorithm identifies fake users on social networks
Apr 19, 8:00 am
19 must-see concerts in Israel this summer
Apr 18, 11:53 am
Fox remaking Israeli TV show; 2 other shows win at Cannes
Apr 18, 11:47 am
Maya Sickle, 8½, talks about growing up Israeli
Most
-
1
-
2
-
3
-
4
-
5
Comments